Valiant Laboratories

Valiant Laboratories Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 397.73 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -59.66 % — a change of -766.63% (higher).

Cash Conversion

397.73 %

YoY

-766.63%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Valiant Laboratories is 2026 397.73 % . Cash Conversion Rate (OCF/Net Income) of Valiant Laboratories was 2025 -59.66 % . It decreases by -766.63% higher compared to the previous year.

The Valiant Laboratories Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2021
29.77 INR
Jan 1, 2022
8.19 INR
Jan 1, 2023
193.29 INR
Jan 1, 2024
589.92 INR
Jan 1, 2025
-59.66 INR
Jan 1, 2026
397.73 INR
The Valiant Laboratories Cash Conversion history
YEARCash ConversionYoY
397.73 %-766.63%
-59.66 %-110.11%
589.92 %+205.20%
193.29 %+2,261.05%
8.19 %-72.50%
29.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Cash Conversion Rate (OCF/Net Income) of Valiant Laboratories is 397.73 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Valiant Laboratories changed from -59.66 % to 397.73 %, representing a -766.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Valiant Laboratories

All Key Metrics — Valiant Laboratories